COVID-19-Influenza Combination (CIC) Vaccine
COVID-19 and Seasonal Influenza
Key Facts
About Novavax
Novavax is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel vaccines to prevent serious infectious diseases. Its core technology platform combines recombinant nanoparticle antigens with its patented saponin-based Matrix-M™ adjuvant to stimulate robust immune responses. The company achieved a major milestone with the global authorization of its COVID-19 vaccine and is now advancing a diversified pipeline targeting respiratory viruses. Novavax's strategic direction involves expanding the utility of its platform, pursuing combination vaccines, and establishing its commercial presence.
View full company profile